Metabolism of prostaglandins A1 and E1 in man
- PMID: 1202078
- PMCID: PMC333118
- DOI: 10.1172/JCI108221
Metabolism of prostaglandins A1 and E1 in man
Abstract
To investigate the in vivo whole blood metabolic clearance rates and sites of metabolism of prostaglandins A1 and E1 in man, constant infusions of the tritiated compounds were administered to normal subjects and to patients undergoing cardiac catheterization. The whole blood metabolic clearance rate of [3H]prostaglandin A1 in eight men was 5,003 +/- 864 liters/day (SD) or 2,546 +/- 513 liters/day per m2 (SD). Nonradioactive prostaglandin A1 was similarly infused in two subjects, and the metabolic clearance rates were determined, utilizing a specific radioimmunoassay. The clearance rates with this method correlated closely with those determined by the isotope infusions. Extraction studies of prostaglandin A1 showed that pulmonary, splanchnic, renal, and extremity perfusions resulted in 8.1 +/- 4.1, 56.1 +/- 10.1, 50.3 +/- 3.4, and 34.4 +/- 5.9% (SEM) removal, respectively. With [3H]=prostaglandin E1, the whole blood metabolic clearance rate was determined from the pulmonary artery concentration in three patients and averaged 4,832 +/- 1,518 liters/day (SD) or 2,686 +/- 654 liters/day per m2 (SD). Pulmonary extraction was 67.8 +/- 6.8% (SEM) and extremity removal averaged 6.6 +/- 4.9% (SEM). These results indicate that A prostaglandins are metabolized by several organs, such as the liver and kidney, and possibly by intravascular pathways as well. In man, the E prostaglandins are primarily metabolized by the lung, but extraction is not complete and approximately one-third may escape lung metabolism. Thus, these findings suggest that both E and A prostaglandins in the venous circulation may reach the systemic circulation in man.
Similar articles
-
Fate of prostaglandins E(1) and A(1) in the human pulmonary circulation.Surgery. 1977 Jun;81(6):716-22. Surgery. 1977. PMID: 871015
-
Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog.J Clin Invest. 1989 Feb;83(2):623-8. doi: 10.1172/JCI113926. J Clin Invest. 1989. PMID: 2521490 Free PMC article.
-
Metabolism of prostaglandins A and E in the perfused rabbit lung and the effects of selected inhibitors.J Pharmacol Exp Ther. 1976 Sep;198(3):716-24. J Pharmacol Exp Ther. 1976. PMID: 978471
-
[Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].Wien Klin Wochenschr. 1998 Jul 31;110(13-14):473-8. Wien Klin Wochenschr. 1998. PMID: 9746960 German.
-
Prostaglandins and related compounds in the perinatal pulmonary circulation.Pediatr Pharmacol (New York). 1984;4(2):129-42. Pediatr Pharmacol (New York). 1984. PMID: 6384905 Review.
Cited by
-
Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.Drugs Aging. 1996 Jan;8(1):56-74. doi: 10.2165/00002512-199608010-00009. Drugs Aging. 1996. PMID: 8785470 Review.
-
The effect of intraportal PGE1 on warm ischemic liver damage.Surg Today. 1994;24(11):1028-30. doi: 10.1007/BF02215820. Surg Today. 1994. PMID: 7772903
-
Degradation of porstaglandin F2alpha in the human pulmonary circulation.Thorax. 1976 Dec;31(6):713-9. doi: 10.1136/thx.31.6.713. Thorax. 1976. PMID: 1013942 Free PMC article.
-
Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease.Clin Immunol. 2015 Dec;161(2):291-9. doi: 10.1016/j.clim.2015.09.008. Epub 2015 Sep 25. Clin Immunol. 2015. PMID: 26408955 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of vasodilators. Part II.Clin Pharmacokinet. 1998 Jul;35(1):9-36. doi: 10.2165/00003088-199835010-00002. Clin Pharmacokinet. 1998. PMID: 9673832 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources